News
17h
Medpage Today on MSNNovel Vaccine Shows Promise in Pancreatic Cancer
An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...
Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...
16h
GlobalData on MSNElicio’s peptide cancer vaccine shows survival benefit in Phase I trial
The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...
The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution ...
Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...
Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.
11h
TipRanks on MSNVerastem Unveils Promising VS-7375 Study Results
Verastem ( ($VSTM) ) just unveiled an announcement. On August 13, 2025, Verastem announced updated safety and efficacy data from the VS-7375 Phase ...
A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...
Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing ...
Research and development (R&D) expenses were $1.0 million for the quarter ended June 30, 2025 compared to $0.8 million for the quarter ended June 30, 2024. The $0.2 million increase was primarily due ...
US sprinter and Olympic silver medalist Fred Kerley has been suspended for a violation of anti-doping procedures, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results